Valuation: BioNTech SE

Market Cap 20.06B 23.14B 18.8B 17.15B 32.26B 2,209B 32.78B 221B 86.44B 1,106B 86.88B 85B 3,688B P/E 2026 *
-14.5x
P/E 2027 * -15.1x
Enterprise Value 9.28B 10.71B 8.7B 7.93B 14.92B 1,022B 15.16B 102B 39.99B 511B 40.19B 39.32B 1,706B EV / Sales 2026 *
5.07x
EV / Sales 2027 * 5.69x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week+1.02%
Current month+1.70%
1 month+2.28%
3 months-0.12%
6 months-12.99%
Current year-3.24%
1 week 91.69
Extreme 91.69
94.25
1 month 88.2
Extreme 88.2
94.41
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
388
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%+1.02%-18.32%-13.84% 23.14B
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.70%-2.83%+33.24%+62.24% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
+0.10%+1.40%+38.98%-20.04% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
-5.38%-0.59%+35.86%+195.96% 11.72B
Average -1.15%+3.60%+51.32%+201.48% 27.82B
Weighted average by Cap. -0.64%+3.46%+50.02%+164.43%

Financials

2026 *2027 *
Net sales 1.83B 2.11B 1.72B 1.56B 2.94B 202B 2.99B 20.2B 7.89B 101B 7.93B 7.75B 336B 1.86B 2.15B 1.75B 1.59B 3B 205B 3.05B 20.58B 8.03B 103B 8.07B 7.9B 343B
Net income -1.34B -1.55B -1.26B -1.15B -2.16B -148B -2.19B -14.8B -5.78B -73.89B -5.81B -5.68B -246B -1.34B -1.55B -1.26B -1.14B -2.15B -147B -2.19B -14.78B -5.77B -73.81B -5.8B -5.67B -246B
Net Debt -10.78B -12.44B -10.1B -9.21B -17.34B -1,187B -17.61B -119B -46.45B -594B -46.69B -45.68B -1,982B -9.44B -10.89B -8.85B -8.07B -15.19B -1,040B -15.43B -104B -40.69B -520B -40.9B -40.01B -1,736B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
13/08/26 USD 92.12 -0.67% 988,541
12/08/26 USD 92.74 -0.06% 476,504
11/08/26 USD 92.80 0.00% 705,979
10/08/26 USD 92.80 -0.93% 731,127
07/08/26 USD 93.67 +2.72% 1,427,941
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.85EUR
Average target price
104.26EUR
Spread / Average Target
+30.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock